Non-Hodgkin lymphoma

Non-Hodgkin lymphoma
Synonyms	Non-Hodgkin disease
Micrograph of mantle cell lymphoma, a type of non-Hodgkin lymphoma. Terminal ileum. H&E stain.
Specialty	Hematology and oncology
Symptoms	Enlarged lymph nodes, fever, night sweats, weight loss, tiredness, itching[1]
Usual onset	65–75 years old[2]
Risk factors	Poor immune function, autoimmune diseases, Helicobacter pylori infection, hepatitis C, obesity, Epstein-Barr virus infection[1][3]
Diagnostic method	Bone marrow or lymph node biopsy[1]
Treatment	Chemotherapy, radiation, immunotherapy, targeted therapy, stem cell transplantation, surgery, watchful waiting[1]
Prognosis	Five-year survival rate 71% (USA)[2]
Frequency	4.3 million (affected during 2015)[4]
Deaths	231,400 (2015)[5]

Non-Hodgkin lymphoma (NHL) is a group of blood cancers that includes all types of lymphoma except Hodgkin's lymphomas.^[1] Symptoms include enlarged lymph nodes, fever, night sweats, weight loss and tiredness.^[1] Other symptoms may include bone pain, chest pain or itchiness.^[1] Some forms are slow-growing, while others are fast-growing.^[1]

Lymphomas are types of cancer that develop from lymphocytes, a type of white blood cell.^[2] Risk factors include poor immune function, autoimmune diseases, Helicobacter pylori infection, hepatitis C, obesity and Epstein-Barr virus infection.^[1][3] The World Health Organization (WHO) classifies lymphomas into five major groups, including one for Hodgkin's lymphoma.^[6] Within the four groups for NHL, there are over 60 specific types of lymphoma.^[7][8] Diagnosis is by examination of a bone marrow or lymph node biopsy.^[1]Medical imaging is done to help with cancer staging.^[1]

Treatment depends on whether the lymphoma is slow- or fast-growing and if it is in one area or many areas.^[1] Treatments may include chemotherapy, radiation, immunotherapy, targeted therapy, stem cell transplantation, surgery or watchful waiting.^[1] If the blood becomes overly thick due to high numbers of antibodies, plasmapheresis may be used.^[1] Radiation and some chemotherapy, however, increase the risk of other cancers, heart disease or nerve problems over the subsequent decades.^[1]

In 2015, about 4.3 million people had non-Hodgkin lymphoma, and 231,400 died.^[4][5] In the United States, 2.1% of people are affected at some point in their life.^[2] The most common age of diagnosis is between 65 and 75 years old.^[2] The five-year survival rate in the United States is 71%.^[2]

Contents

• 
  1 Signs and symptoms
  


• 
  2 Causes
  
  
  
  • 
    2.1 Familial component
    
  
  
  • 
    2.2 HIV/AIDS
    
  
  
  
  


• 
  3 Treatment
  


• 
  4 Epidemiology
  
  
  
  • 
    4.1 United States
    
  
  
  • 
    4.2 Canada
    
  
  
  • 
    4.3 United Kingdom
    
  
  
  
  


• 
  5 History
  


• 
  6 References
  


• 
  7 External links
  

Signs and symptoms

The signs and symptoms of non-Hodgkin's lymphoma vary depending upon its location within the body. Symptoms include enlarged lymph nodes, fever, night sweats, weight loss, and tiredness. Other symptoms may include bone pain, chest pain, or itchiness. Some forms are slow growing while others are fast growing.^[1] Enlarged lymph nodes may cause lumps to be felt under the skin when they are close to the surface of the body. Lymphomas in the skin may also result in lumps, which are commonly itchy, red or purple. Lymphomas in the brain can cause weakness, seizures, problems with thinking and personality changes.^{[medical citation needed]}

Causes

The many different forms of lymphoma probably have different causes. These possible causes and associations with at least some forms of NHL include the following:

• Infectious agents:
  
  
  
  • 
    Epstein-Barr virus: associated with Burkitt's lymphoma, Hodgkin's lymphoma, follicular dendritic cell sarcoma, extranodal NK-T-cell lymphoma^[9]
    
  
  
  • 
    Human T-cell leukemia virus: associated with adult T-cell lymphoma
    
  
  
  • 
    Helicobacter pylori: associated with gastric lymphoma
    
  
  
  • 
    HHV-8: associated with primary effusion lymphoma, multicentric Castleman disease
    
  
  
  • 
    Hepatitis C virus: associated with splenic marginal zone lymphoma, lymphoplasmacytic lymphoma and diffuse large B-cell lymphoma^[10]
    
  
  
  • 
    HIV infection^[11]
    
  
  
  
  


• Some chemicals, like polychlorinated biphenyls (PCBs),^[12][13][14]diphenylhydantoin, dioxin, and phenoxy herbicides.


• Medical treatments, like radiation therapy and chemotherapy
  


• Genetic diseases, like Klinefelter's syndrome, Chédiak-Higashi syndrome, ataxia telangiectasia syndrome
  


• Autoimmune diseases, like Sjögren’s syndrome, celiac disease, rheumatoid arthritis, and systemic lupus erythematosus.^[15][16]
  

Familial component

Familial lymphoid cancer is rare. The familial risk of lymphoma is elevated for multiple lymphoma subtypes, suggesting a shared genetic cause. However, a family history of a specific subtype is most strongly associated with risk for that subtype, indicating that these genetic factors are subtype-specific. Genome-wide association studies (GWAS) have successfully identified 67 single nucleotide polymorphisms (SNPs) from 41 loci, most of which are subtype specific.^[17]

HIV/AIDS

The Center for Disease Control and Prevention (CDC) included certain types of non-Hodgkin's lymphoma as AIDS-defining cancers in 1987.^[18] Immune suppression rather than HIV itself is implicated in the pathogenesis of this malignancy, with a clear correlation between the degree of immune suppression and the risk of developing NHL. Additionally, other retroviruses such as HTLV may be spread by the same mechanisms that spread HIV, leading to an increased rate of co-infection.^[19] The natural history of HIV infection has been greatly changed over time. As a consequence, rates of non-Hodgkin's lymphoma (NHL) in people infected with HIV has significantly declined in recent years.^[11]

Treatment

The traditional treatment of NHL includes chemotherapy and stem cell transplants. The most common chemotherapy used for B-cell non-Hodgkin lymphoma is R-CHOP, which is a regiment of four drugs (cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab).^[20] There have been developments in immunotherapy. Bendamustine is also used.

Epidemiology

Globally, as of 2010, there were 210,000 deaths, up from 143,000 in 1990.^[21]

Rates of Non-Hodgkin lymphoma increases steadily with age.^[15] Up to 45 years NHL is more common among males than females.^[22]

United States

In the US, data from 2007–2011 show that there were about 19.7 cases of NHL per 100,000 adults per year, 6.3 deaths per 100,000 adults per year. About 2.1 percent of men and women are diagnosed with NHL at some point during their lifetime, and there were around 530,919 people living with non-Hodgkin lymphoma.^[23]

American Cancer Society lists Non-Hodgkin lymphoma as one of the most common cancers in the United States, accounting for about 4% of all cancers^[24]. 

Canada

In Canada, NHL is the fifth most common cancer in males and sixth most common cancer in females. The lifetime probability of developing a lymphoid cancer is 1 in 44 for males, and 1 in 51 for females.^[25]

United Kingdom

NHL is the sixth most common cancer in the UK (around 12,800 people were diagnosed with the disease in 2011), and it is the eleventh most common cause of cancer death (around 4,700 people died in 2012).^[26]

History

While consensus was rapidly reached on the classification of Hodgkin lymphoma, there remained a large group of very different diseases requiring further classification. The Rappaport classification, proposed by Henry Rappaport in 1956 and 1966, became the first widely accepted classification of lymphomas other than Hodgkin. Following its publication in 1982, the Working Formulation became the standard classification for this group of diseases. It introduced the term non-Hodgkin lymphoma or NHL and defined three grades of lymphoma.^{[citation needed]}

NHL consists of many different conditions that have little in common with each other. They are grouped by their aggressiveness. Less aggressive non-Hodgkin lymphomas are compatible with a long survival while more aggressive non-Hodgkin lymphomas can be rapidly fatal without treatment. Without further narrowing, the label is of limited usefulness for patients or doctors. The subtypes of lymphoma are listed there.^{[citation needed]}

Nevertheless, the Working Formulation and the NHL category continue to be used by many. To this day, lymphoma statistics are compiled as Hodgkin's versus non-Hodgkin lymphomas by major cancer agencies, including the US National Cancer Institute in its SEER program, the Canadian Cancer Society and the IARC.

References

1. 
   ^ ^{abcdefghijklmnop} "Adult Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version". NCI. August 3, 2016. Archived from the original on 16 August 2016. Retrieved 13 August 2016..mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"""""""'""'"}.mw-parser-output .citation .cs1-lock-free a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .citation .cs1-lock-subscription a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}
   


2. 
   ^ ^abcdef "SEER Stat Fact Sheets: Non-Hodgkin Lymphoma". NCI. April 2016. Archived from the original on 6 July 2014. Retrieved 13 August 2016.
   


3. 
   ^ ^ab World Cancer Report 2014. World Health Organization. 2014. pp. Chapter 2.4, 2.6. ISBN 978-9283204299.
   


4. 
   ^ ^ab GBD 2015 Disease and Injury Incidence and Prevalence, Collaborators. (8 October 2016). "Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet. 388 (10053): 1545–1602. doi:10.1016/S0140-6736(16)31678-6. PMC 5055577. PMID 27733282.
   


5. 
   ^ ^ab GBD 2015 Mortality and Causes of Death, Collaborators. (8 October 2016). "Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet. 388 (10053): 1459–1544. doi:10.1016/s0140-6736(16)31012-1. PMC 5388903. PMID 27733281.
   


6. 
   ^ "Adult Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version". NCI. June 1, 2016. Archived from the original on 12 August 2016. Retrieved 13 August 2016.
   


7. 
   ^ "Different types of non Hodgkin lymphoma". Cancer Research UK. Archived from the original on 14 August 2016. Retrieved 13 August 2016.
   


8. 
   ^ Bope, Edward T.; Kellerman, Rick D. (2015). Conn's Current Therapy 2016. Elsevier Health Sciences. p. 878. ISBN 9780323355353. Archived from the original on 2017-09-10.
   


9. 
   ^ Maeda E, Akahane M, Kiryu S, Kato N, Yoshikawa T, Hayashi N, Aoki S, Minami M, Uozaki H, Fukayama M, Ohtomo K (2009). "Spectrum of Epstein-Barr virus-related diseases: A pictorial review". Japanese Journal of Radiology. 27 (1): 4–19. doi:10.1007/s11604-008-0291-2. PMID 19373526.
   


10. 
    ^ Peveling-Oberhag J, Arcaini L, Hansmann ML, Zeuzem S (2013). "Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management". Journal of Hepatology. 59 (1): 169–177. doi:10.1016/j.jhep.2013.03.018. PMID 23542089.
    


11. 
    ^ ^ab Pinzone MR, Fiorica F, Di Rosa M, Malaguarnera G, Malaguarnera L, Cacopardo B, Zanghì G, Nunnari G (October 2012). "Non-AIDS-defining cancers among HIV-infected people". Eur Rev Med Pharmacol Sci. 16 (10): 1377–88. PMID 23104654.
    


12. 
    ^ Kramer S, Hikel SM, Adams K, Hinds D, Moon K (2012). "Current Status of the Epidemiologic Evidence Linking Polychlorinated Biphenyls and Non-Hodgkin Lymphoma, and the Role of Immune Dysregulation". Environmental Health Perspectives. 120 (8): 1067–75. doi:10.1289/ehp.1104652. PMC 3440083. PMID 22552995.
    


13. 
    ^ Zani C, Toninelli G, Filisetti B, Donato F (2013). "Polychlorinated biphenyls and cancer: an epidemiological assessment". J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 31 (2): 99–144. doi:10.1080/10590501.2013.782174. PMID 23672403.
    


14. 
    ^ Lauby-Secretan B, Loomis D, Grosse Y, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L, Guha N, Baan R, Mattock H, Straif K (2013). "Carcinogenicity of polychlorinated biphenyls and polybrominated biphenyls". Lancet Oncology. 14 (4): 287–288. doi:10.1016/s1470-2045(13)70104-9. PMID 23499544.
    


15. 
    ^ ^ab Tobias, J; Hochhauser D. (2015). Cancer and its Management (7th ed.). Wiley-Blackwell. ISBN 9781118468715.
    


16. 
    ^ Arnold S Freedman, Lee M Nadler (2000). "Chapter 130: Non–Hodgkin's Lymphomas". In Kufe DW, Pollock RE, Weichselbaum RR, Bast RC Jr, Gansler TS, Holland JF, Frei E III. Holland-Frei Cancer Medicine (5th ed.). Hamilton, Ont: B.C. Decker. ISBN 1-55009-113-1. Archived from the original on 2017-09-10.
    


17. 
    ^ Cerhan, James (Nov 12, 2015). "Familial predisposition and genetic risk factors for lymphoma". Blood. 126 (20): 2267-2273. doi:10.1182/blood-2015-04-537498. PMC 4643002. PMID 26405224.
    


18. 
    ^ "Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. Council of State and Territorial Epidemiologists; AIDS Program, Center for Infectious Diseases" (PDF). Morbidity and Mortality Weekly Report. 36 (Suppl 1): 1S–15S. 1987. PMID 3039334. Archived (PDF) from the original on 2017-06-09.
    


19. 
    ^ Lee, Belinda; Bower, Mark; Newsom-Davis, Thomas; Nelson, Mark (2010). "HIV-related lymphoma". HIV Therapy. 4 (6): 649–659. doi:10.2217/hiv.10.54.
    


20. 
    ^ "Treating B-Cell Non-Hodgkin Lymphoma". www.cancer.org. Retrieved 2019-02-05.
    


21. 
    ^ Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, et al. (Dec 15, 2012). "Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010". Lancet. 380 (9859): 2095–128. doi:10.1016/S0140-6736(12)61728-0. PMID 23245604.
    


22. 
    ^ Bleyer, W Archie, Barr, Ronald D. Cancer in Adolescents and Young Adults. Springer, 2007, p. 129.
    


23. 
    ^ NIH NCI Surveillance, Epidemiology, and End Results Program. Posted to SEER website April 2014. SEER Stat Fact Sheets: Non-Hodgkin Lymphoma Archived 2014-07-06 at the Wayback Machine Page accessed February 26, 2015
    


24. 
    ^ "What Are the Key Statistics About Non-Hodgkin Lymphoma?". www.cancer.org. Retrieved 2018-01-05.
    


25. 
    ^ "Canadian Cancer Statistics". www.cancer.ca. Retrieved 2018-02-08.
    


26. 
    ^ "Non-hodgkin lymphoma statistics". Cancer Research UK. Archived from the original on 7 October 2014. Retrieved 28 October 2014.
    

External links

Classification	D ICD-10: C82-C85 ICD-9-CM: 200, 202 ICD-O: 9591/3 OMIM: 605027 MeSH: D008228 DiseasesDB: 9065
External resources	MedlinePlus: 000581 eMedicine: med/1363 ped/1343 Patient UK: Non-Hodgkin lymphoma NCI: Non-Hodgkin lymphoma

• 
  Non-Hodgkin Lymphoma at American Cancer Society
  


• 
  Non-Hodgkins Lymphoma from Cancer.net (American Society of Clinical Oncology)


• 
  Patient information on non-Hodgkin lymphoma from The Lymphoma Association


• Lymphoma Association – Specialist UK charity providing free information and support to patients, their families, friends and carers

v t e Hematological malignancy/leukemia histology (ICD-O 9590–9989, C81–C96, 200–208) Lymphoid/Lymphoproliferative, Lymphomas/Lymphoid leukemias (9590–9739, 9800–9839)
B cell (lymphoma, leukemia) (most CD19 CD20) By development/ marker TdT+ ALL (Precursor B acute lymphoblastic leukemia/lymphoma) CD5+ naive B cell (CLL/SLL) mantle zone (Mantle cell) CD22+ Prolymphocytic CD11c+ (Hairy cell leukemia) CD79a+ germinal center/follicular B cell (Follicular Burkitt's GCB DLBCL Primary cutaneous follicle center lymphoma) marginal zone/marginal zone B-cell (Splenic marginal zone MALT Nodal marginal zone Primary cutaneous marginal zone lymphoma) RS (CD15+, CD30+) Classic Hodgkin's lymphoma (Nodular sclerosis) CD20+ (Nodular lymphocyte predominant Hodgkin's lymphoma) PCDs/PP (CD38+/CD138+) see immunoproliferative immunoglobulin disorders By infection KSHV (Primary effusion) EBV Lymphomatoid granulomatosis Post-transplant lymphoproliferative disorder Classic Hodgkin's lymphoma Burkitt's lymphoma HCV Splenic marginal zone lymphoma HIV (AIDS-related lymphoma) Helicobacter pylori (MALT lymphoma) Cutaneous Diffuse large B-cell lymphoma Intravascular large B-cell lymphoma Primary cutaneous marginal zone lymphoma Primary cutaneous immunocytoma Plasmacytoma Plasmacytosis Primary cutaneous follicle center lymphoma T/NK T cell (lymphoma, leukemia) (most CD3 CD4 CD8) By development/ marker TdT+: ALL (Precursor T acute lymphoblastic leukemia/lymphoma) prolymphocyte (Prolymphocytic) CD30+ (Anaplastic large-cell lymphoma Lymphomatoid papulosis type A) Cutaneous MF+variants indolent: Mycosis fungoides Pagetoid reticulosis Granulomatous slack skin aggressive: Sézary disease Adult T-cell leukemia/lymphoma Non-MF CD30-: Non-mycosis fungoides CD30− cutaneous large T-cell lymphoma Pleomorphic T-cell lymphoma Lymphomatoid papulosis type B CD30+: CD30+ cutaneous T-cell lymphoma Secondary cutaneous CD30+ large-cell lymphoma Lymphomatoid papulosis type A Other peripheral Hepatosplenic Angioimmunoblastic Enteropathy-associated T-cell lymphoma Peripheral T-cell lymphoma not otherwise specified (Lennert lymphoma) Subcutaneous T-cell lymphoma By infection HTLV-1 (Adult T-cell leukemia/lymphoma) NK cell/ (most CD56) Aggressive NK-cell leukemia Blastic NK cell lymphoma T or NK EBV (Extranodal NK-T-cell lymphoma/Angiocentric lymphoma) Large granular lymphocytic leukemia Lymphoid+ myeloid Acute biphenotypic leukaemia Lymphocytosis Lymphoproliferative disorders (X-linked lymphoproliferative disease Autoimmune lymphoproliferative syndrome) Leukemoid reaction Diffuse infiltrative lymphocytosis syndrome
Cutaneous lymphoid hyperplasia	Cutaneous lymphoid hyperplasia with bandlike and perivascular patterns with nodular pattern Jessner lymphocytic infiltrate of the skin

Authority control	BNF: cb11958249q (data) GND: 4115403-4

This page is only for reference, If you need detailed information, please check here